Norway · Delayed Price · Currency is NOK Lytix Biopharma ASA Earnings Call Transcripts
Fiscal Year 2026
-
Ruxotemitide showed strong phase II results in melanoma and basal cell carcinoma, with durable responses and systemic immune activation. Financially, Q1 2026 saw increased R&D spending and a strengthened cash position, supporting ongoing clinical development and upcoming registrational studies.
Fiscal Year 2025
-
Strong clinical data and a NOK 77 million capital raise have positioned the company for pivotal studies and partnerships, with a cash runway into 2027. Interim results in key trials are promising, and multiple assets are validated as multi-billion-dollar opportunities.
-
Strong clinical data for ruxotemitide in BCC and melanoma support advancement toward commercialization, with stable financials and sufficient funding through 2026. Phase III studies are planned, with partnerships considered for financing.
-
Q2 saw a sharply reduced net loss due to a one-off accrual reversal, with a strong cash position extending into 2026. Key milestones ahead include interim NeoLIPA data in November and phase III plans for LTX-315 in BCC, while LTX-401 advances preclinically.
-
Strong phase II results for LTX-315 in basal cell carcinoma and melanoma, with a robust cash position supporting operations into 2026. Key milestones include interim NeoLIPA data in Q3 2025 and a phase III update for LTX-315 mid-2025.
Fiscal Year 2024
-
Strong phase II results for LTX-315 in BCC and ongoing melanoma studies highlight robust clinical progress, supported by a NOK 111 million capital raise and a solid financial runway into 2026. Strategic focus remains on advancing clinical programs and commercialization.
-
Strong phase II results for LTX-315 in melanoma and basal cell carcinoma highlight robust clinical progress, with financial stability supported by a recent share offering and milestone-driven partnerships. Cash runway extends into 2025, and multiple studies and regulatory milestones are on track.
-
Strong clinical progress with LTX-315 in BCC and melanoma, including 86% tumor reduction in BCC and durable disease control in late-stage melanoma. Operating expenses declined, cash runway extended into 2025, and a new LTX-401 formulation shows promise.
-
Phase 2 results for LTX-315 in BCC showed an 86% average tumor reduction and complete elimination in over half of patients, with no serious side effects. LTX-315 is positioned as a potential first-line, less invasive treatment, with significant commercial and clinical milestones ahead.